First Needle-Free Patch RSV Vaccine Being Created
The U.S. National Institutes of Health (NIH) has granted the Biotech company Vaxxas Pty. Ltd. of Australia a worldwide license to a respiratory syncytial virus (RSV) antigen known as DS2. The license will allow for the firm to create the first needle-free and room-temperature stable RSV vaccine using a novel and “cutting edge” high-density microarray […]
First Needle-Free Patch RSV Vaccine Being Created Read More »